These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39253)

  • 1. Pertussis vaccine--an analysis of benefits, risks and costs.
    Koplan JP; Schoenbaum SC; Weinstein MC; Fraser DW
    N Engl J Med; 1979 Oct; 301(17):906-11. PubMed ID: 39253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertussis and pertussis vaccine: further analysis of benefits, risks and costs.
    Hinman AR; Koplan JP
    Dev Biol Stand; 1985; 61():429-37. PubMed ID: 3938968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies.
    de Greeff SC; Lugnér AK; van den Heuvel DM; Mooi FR; de Melker HE
    Vaccine; 2009 Mar; 27(13):1932-7. PubMed ID: 19368774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertussis vaccination strategies for neonates--an exploratory cost-effectiveness analysis.
    Scuffham PA; McIntyre PB
    Vaccine; 2004 Jul; 22(21-22):2953-64. PubMed ID: 15246632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and risks of immunization against pertussis.
    Stuart-Harris C
    Dev Biol Stand; 1979; 43():75-83. PubMed ID: 520687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of pertussis vaccination in adults.
    Lee GM; Murphy TV; Lett S; Cortese MM; Kretsinger K; Schauer S; Lieu TA
    Am J Prev Med; 2007 Mar; 32(3):186-193. PubMed ID: 17296470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pertussis vaccine controversy.
    Hinman AR
    Public Health Rep; 1984; 99(3):255-9. PubMed ID: 6429722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis.
    Iskedjian M; De Serres G; Einarson TR; Walker JH
    Vaccine; 2010 Jan; 28(3):714-23. PubMed ID: 19895923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age at pertussis immunization as it relates to current epidemiology and disease control.
    Funkhouser AW; Wassilak SG; Hinman AR; Orenstein WA; Mortimer EA
    Tokai J Exp Clin Med; 1988; 13 Suppl():111-5. PubMed ID: 3273610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs.
    Hinman AR; Koplan JP
    JAMA; 1984 Jun; 251(23):3109-13. PubMed ID: 6427489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Present and future of oral pertussis vaccination].
    Falk W; Höfler KH; Rosanelli K; Kurz R
    Fortschr Med; 1981 Sep; 99(34):1363-6. PubMed ID: 6116657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
    Purdy KW; Hay JW; Botteman MF; Ward JI
    Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands.
    Westra TA; de Vries R; Tamminga JJ; Sauboin CJ; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1479-95. PubMed ID: 20728761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of immunization programs in Colombia.
    Creese AL; Domínguez-Uga MA
    Bull Pan Am Health Organ; 1987; 21(4):377-94. PubMed ID: 3125875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epidemiologic development of whooping cough and tetanus with regard to programs of childhood immunization].
    Ruiz Peláez ML; Petit C; Rosado Martín M; Bolumar F; Nájera E
    Rev Sanid Hig Publica (Madr); 1984; 58(11-12):1133-48. PubMed ID: 6549609
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada.
    Bettinger JA; Halperin SA; De Serres G; Scheifele DW; Tam T
    Pediatr Infect Dis J; 2007 Jan; 26(1):31-5. PubMed ID: 17195702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.